Immunoglobulin E-mediated mast cell activation pathway

Immunoglobulin E-mediated mast cell activation describes a critical immunological pathway underlying acute allergic responses and other inflammatory conditions. Mast cells, which are tissue-resident immune cells, express high-affinity FcεRI receptors on their surface that bind IgE antibodies produced by B cells after Th2 stimulation. Upon exposure to specific antigens, these antigens cross-link the IgE-FcεRI complexes, rapidly triggering signal transduction cascades involving Syk kinase, LAT, NTAL, PLC, PI3K, and downstream calcium influx and protein kinase activation. This results in the immediate release (degranulation) of preformed mediators such as histamine and tryptase, and the delayed synthesis of cytokines and lipid mediators. These events produce typical allergy symptoms (itching, swelling, bronchoconstriction) and also play roles in chronic inflammatory diseases. Therapeutics targeting IgE itself (e.g., omalizumab) or components of the pathway aim to blunt this activation, reducing severity and frequency of allergic and inflammatory events[1][3][5][2].

Other names

IgE/FcεRI signaling pathwayIgE-mediated mast cell activationIgE-dependent mast cell degranulation pathway

IgE neutralization (reduces circulating IgE so less can bind FcεRI on mast cells); FcεRI antagonism/blockade (prevents activation by stopping IgE binding/antigen cross-linking); Mast cell desensitization (reduces FcεRI receptor numbers or sensitivity)